Mico BioMed Co. Ltd. (KQ:214610) — Market Cap & Net Worth
Market Cap & Net Worth: Mico BioMed Co. Ltd. (214610)
Mico BioMed Co. Ltd. (KQ:214610) has a market capitalization of $13.00 Million (₩19.18 Billion) as of May 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26218 globally and #1955 in its home market, demonstrating a -9.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mico BioMed Co. Ltd.'s stock price ₩2290.00 by its total outstanding shares 8376318 (8.38 Million). Analyse Mico BioMed Co. Ltd. operating cash flow efficiency to see how efficiently the company converts income to cash.
Mico BioMed Co. Ltd. Market Cap History: 2020 to 2026
Mico BioMed Co. Ltd.'s market capitalization history from 2020 to 2026. Data shows change from $40.99 Million to $13.00 Million (-22.09% CAGR).
Index Memberships
Mico BioMed Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.00% | #1076 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.00% | #1076 of 1384 |
Weight: Mico BioMed Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mico BioMed Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mico BioMed Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Mico BioMed Co. Ltd.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $40.99 Million | $45.67 Billion | -$5.78 Billion | 0.00x | N/A |
| 2021 | $33.16 Million | $30.30 Billion | -$10.58 Billion | 0.00x | N/A |
| 2022 | $17.49 Million | $16.11 Billion | -$38.89 Billion | 0.00x | N/A |
| 2023 | $10.51 Million | $5.37 Billion | -$25.77 Billion | 0.00x | N/A |
| 2024 | $7.93 Million | $4.64 Billion | -$29.93 Billion | 0.00x | N/A |
Competitor Companies of 214610 by Market Capitalization
Companies near Mico BioMed Co. Ltd. in the global market cap rankings as of May 3, 2026.
Key companies related to Mico BioMed Co. Ltd. by market ranking:
- New York Times Company (NYSE:NYT): Ranked #1957 globally with a market cap of $11.88 Billion USD.
- Pearson plc (F:PESA): Ranked #2822 globally with a market cap of $7.11 Billion USD ( €6.08 Billion EUR).
- Schibsted ASA B (OL:SCHB): Ranked #3921 globally with a market cap of $4.37 Billion USD ( Nkr41.56 Billion NOK).
- Springer Nature AG & Co KGaA (F:SPG): Ranked #3926 globally with a market cap of $4.36 Billion USD ( €3.73 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #1957 | New York Times Company | NYSE:NYT | $11.88 Billion | $78.72 |
| #2822 | Pearson plc | F:PESA | $7.11 Billion | €12.30 |
| #3921 | Schibsted ASA B | OL:SCHB | $4.37 Billion | Nkr321.80 |
| #3926 | Springer Nature AG & Co KGaA | F:SPG | $4.36 Billion | €19.86 |
Mico BioMed Co. Ltd. Historical Marketcap From 2020 to 2026
Between 2020 and today, Mico BioMed Co. Ltd.'s market cap moved from $40.99 Million to $ 13.00 Million, with a yearly change of -22.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩13.00 Million | -36.48% |
| 2025 | ₩20.46 Million | +158.05% |
| 2024 | ₩7.93 Million | -24.57% |
| 2023 | ₩10.51 Million | -39.89% |
| 2022 | ₩17.49 Million | -47.25% |
| 2021 | ₩33.16 Million | -19.11% |
| 2020 | ₩40.99 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Mico BioMed Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.00 Million USD |
| MoneyControl | $13.00 Million USD |
| MarketWatch | $13.00 Million USD |
| marketcap.company | $13.00 Million USD |
| Reuters | $13.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more